Program Status
RecruitingPhase
Phase 2Prior Immunotherapy Allowed
YesCRC-directed Trial
YesTags
MSI-H/ MMRd, MSS/ MMRpComments
Trial in Netherlands, for patients with liver mets from colon or rectal cancer that cannot be removed with surgery or thermal ablation.
Patients will be randomized to treatment of the liver lesions with two different ablative techniques: irreversible electroporation (IRE) or stereotactic body radiotherapy (SBRT)
Location | Location Status |
---|---|
Netherlands | |
Amsterdam UMC - location VUmc Amsterdam, Noord Holland 1081 HV |
Recruiting |
Contacts
Inclusion Criteria
Inclusion Criteria:
* Histological documentation of primary colorectal tumor is available;
* 1-3 CRLM visible on ceCT and/or MRI, size 0-5 cm and not eligible for resection or thermal ablation due to location close to a vessel or bile duct;
* Additional CRLM are allowed if considered either resectable or ablatable with a maximum of 10 CRLM. In patients with extrahepatic disease, a maximum of 5 additional CRLM is allowed;
* No or limited extrahepatic disease (1 extrahepatic lesion is allowed, with some exclusions mentioned in the
Exclusion Criteria
exclusion criteria);
* Prior focal liver treatment is allowed;
* Subjects should preferably be treated with neo-adjuvant systemic therapy;
* Subjects with recurrent (either local or distant-hepatic) CRLM after previous focal treatment who are unsuitable for (further) systemic therapy (further downsizing or conversion to resectable disease improbable);
* Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to definite inclusion;
* ASA classification 0 - 3;
* Age >18 years;
* Written informed consent;
Exclusion Criteria:
* Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
* >10 CRLM; >5 CRLM when extra-hepatic disease is present;
* Positive para-aortal lymph nodes, celiac lymph nodes, adrenal metastases, pleural carcinomatosis or peritoneal carcinomatosis;
* Subjects who have progressive disease after neo-adjuvant systemic therapy;
* History of epilepsy;
* History of cardiac disease:
* Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;
* Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites);
* Pregnant or breast-feeding subjects;
* Immunotherapy ≤ 2 weeks prior to the procedure;
* Chemotherapy and/or targeted therapy ≤ 2 weeks prior to the procedure;
* Severe allergy to contrast media not controlled with premedication;
* Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.